Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
Slika profila

Luka Vončina

190

Luka

Vončina

dr. sc.

nije evidentirano
Naziv Akcije
Feng, Y.; Roukas, C.; Russo, M.; Repišti, S.; Džubur Kulenović, A.; Injac Stevović, L.; Konjufca, J., Markovska-Simoska, S.; Novotni, L.; Ristić, I.; Smajić-Mešević, E. et al. Cost-effectiveness of implementing a digital psychosocial intervention for patients with psychotic spectrum disorders in low- and middle-income countries in Southeast Europe: Economic evaluation alongside a cluster randomised trial // European psychiatry, 65 (2022), 1; e56, 12
Bobinac, Ana; Banović, Igor; Atanasijevic, D; Harsanyi, A; Hristova, K; Mardare, I; Vila, M; Kamusheva, M; Dimitrova, M; Fürst, J et al. PRICING AND REIMBURSEMENT OF INNOVATIVE MEDICINES: CHALLENGES AND LESSONS FROM SOUTH-EASTERN EUROPE // Value in health, 24 (2021), JUNE; S180-S181
Vrdoljak, Eduard ; Šekerija, Mario ; Pleština, Stjepko ; Belac Lovasić, Ingrid ; Katalinić Janković, Vera ; Garattini, Livio ; Bobinac, Ana ; Vončina, Luka Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer. // The European journal of health economics, 22 (2021), 3; 393-403. doi: 10.1007/s10198-020-01262-0
Moorkens, Evelien ; Godman, Brian ; Huys, Isabelle ; Hoxha, Iris ; Malaj, Admir ; Keuerleber, Simon ; Stockinger, Silvia ; Mörtenhuber, Sarah ; Dimitrova, Maria ; Tachkov, Konstantin et al. The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures // Frontiers in pharmacology, 11 (2021), 591134, 17. doi: 10.3389/fphar.2020.591134
Vončina, Luka ; Strbad, Tea ; Fürst, Jurij ; Dimitrova, Maria ; Kamusheva, Maria ; Vila, Megi ; Mardare, Ileana ; Hristova, Kristina ; Harsanyi, Andras ; Atanasijević, Dragana et al. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South- Eastern Europe // Applied health economics and health policy, 19 (2021), 6; 915-927. doi: 10.1007/s40258-021-00678-w
Organizacija zdravstvene zaštite i zdravstvena ekonomika / Šogorić, Selma (ur.) Zagreb: Medicinska naklada, 2016
Godman, B ; Wettermark, B ; van Woerkom, M ; Fraeyman, J ; Alvarez- Madrazo, S ; Berg, C ; Bishop, I ; Bucsics, A ; Campbell, S ; Finlayson, AE et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. // Frontiers in pharmacology, 5 (2014), 106-1-106-9. doi: 10.3389/fphar.2014.00106
Vončina, Luka ; Strizrep, T. ; Godman, B. ; Bennie, M. ; Bishop, I. ; Campbell, S. ; Vlahović-Palčevski, Vera ; Gustafsson, L.L. Influence of demand-side measures to enhance renin–angiotensin prescribing efficiency in Europe: implications for the future // Expert Review of Pharmacoeconomics & Outcomes Research, 11 (2014), 4; 469-479. doi: 10.1586/erp.11.42
Vončina, Luka Unemployment as a health-related risk factor / Polašek, Ozren (mentor); Split, Medicinski fakultet u Splitu, . 2013
Godman, B ; Finlayson, AE ; Cheema, PK ; Zebedin-Brandl, E ; Gutiérrez-Ibarluzea, I ; Jones, J ; Malmström, RE ; Asola, E ; Baumgärtel, C ; Bennie, M et al. Personalizing health care: feasibility and future implications // Bmc medicine, 11 (2013), 1; 179-x. doi: 10.1186/1741-7015-11-179
nije evidentirano
nije evidentirano